Clinical trials: Type 2 Diabetic
Diabetes Mellitus, Type 2
Efficacy and Safety of Linagliptin in Combination With Insulin in Patients With Type 2 Diabetes
The objective of the current study is to investigate the efficacy, safety and tolerability of linagliptin (5 mg / once daily) compared to Placebo during long term treatment (52 weeks and longer) in combination with basal insulin…
- Trial name
- NCT00954447
- Testing
- Linagliptin
- Where
- 169 sites in United States, Argentina and 17 more
- Volunteers
- 1,263 people
- Sponsor
- Boehringer Ingelheim
Interaction, Adverse Herb-Drug, Diabetes Mellitus, Type 2
Clinical Evaluation of the Pharmacokinetic Goldenseal-Metformin Interaction in Diabetic Patients
Supplements containing goldenseal, a perennial herb native to North America, have consistently ranked among the top 20 highest selling natural products throughout the last decade.
- Trial name
- NCT05081583
- Testing
- Midazolam Hcl 1Mg/Ml Inj, Goldenseal (Hydrastis canadensis)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Washington State University
Diabetes Mellitus, Type 2
Allogeneic Mesenchymal Human Stem Cells Infusion Therapy for Endothelial DySfunctiOn in Diabetic Subjects
This is a 16 subject trial to demonstrate the safety of allogeneic hMSCs administered via infusion therapy for diabetic subjects with endothelial dysfunction.
- Trial name
- ACESO (NCT02886884)
- Testing
- 20 million Allogeneic Mesenchymal Human Stem Cells, 100 million Allogeneic Mesenchymal Human Stem Cells
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Joshua M Hare
Diabetes Mellitus, Type 2, Newly Diagnosed
Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients
The purpose of this study is to investigate and evaluate the effects of different interventions (1. exenatide, 2. insulin, 3. thiazolidinedione) on glycemic control and β-cell function in newly diagnosed drug-naïve type 2…
- Trial name
- NCT01147627
- Testing
- exenatide injection, Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R, Pioglitazone
- Where
- 25 sites in China
- Volunteers
- 416 people
- Sponsor
- Sun Yat-sen University
Diabetes Mellitus, Type 2
A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263
A study in type 2 diabetic subjects on stable metformin therapy to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of co-administering single and multiple oral doses of GSK1292263
- Trial name
- NCT01128621
- Testing
- GSK1292263, Sitagliptin
- Where
- 2 sites in United States
- Volunteers
- 66 people
- Sponsor
- GlaxoSmithKline
Painful Diabetic Neuropathy
Quantitative Assessment of Painful Diabetic Peripheral Neuropathy After High Frequency Spinal Cord Stimulation
Will participants with painful lower extremity diabetic peripheral neuropathy (DPN) that are treated with high frequency spinal cord stimulation (HF10 SCS) have improvements in lower extremity peripheral nerve function?
- Trial name
- NCT03769675
- Testing
- High Frequency Spinal Cord Stimulator
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Mayo Clinic
Type 2 Diabetes Mellitus, Hypercholesterolemia
Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effects of Colesevelam HCl on Lipids and Glucose on Pre-diabetic Patients.
This is a 16-week double-blind, placebo-controlled (for colesevelam hydrochloride (HCl)) study in the type 2 diabetic subjects and pre-diabetic subjects.
- Conditions
- Type 2 Diabetes Mellitus, Hypercholesterolemia, Pre-diabetes
- Trial name
- NCT00570739
- Testing
- Metformin HCl tablets and Colesevelam tablets, Colesevelam
- Where
- 31 sites in United States, Colombia and 2 more
- Volunteers
- 502 people
- Sponsor
- Daiichi Sankyo
Type 2 Diabetes, Overt Diabetic Nephropathy
Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy
Objective: To evaluate how rosiglitazone does influence the renal plasma flow, the glomerular filtration rate and the degree of proteinuria in type 2 diabetic patients with renal insufficiency due to overt diabetic nephropathy.
- Trial name
- NCT00324675
- Testing
- Rosiglitazone
- Where
- Germany
- Volunteers
- 28 people
- Sponsor
- Technische Universität Dresden
Diabetic Nephropathy
Efficacy and Safety of Canagliflozin (TA-7284) in Patients With Diabetic Nephropathy
The purpose of this study is to evaluate the efficacy and safety of Canagliflozin (TA-7284) in Japanese patients with Diabetic Nephropathy, compared with placebo
- Trial name
- NCT03436693
- Testing
- Canagliflozin
- Where
- 26 sites in Japan
- Volunteers
- 308 people
- Sponsor
- Tanabe Pharma Corporation
Diabetes Mellitus, Type 2
A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes
Description of the real-life treatment of adult patients with type-2 diabetes mellitus (T2DM) receiving Empagliflozin, comparing the characteristics of patients starting Empagliflozin in three time intervals
- Trial name
- EDCOS (NCT04098575)
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 9,571 people
- Sponsor
- Boehringer Ingelheim
Diabetic Autonomic Neuropathy
Bromocriptine-QR Therapy on Sympathetic Tone and Vascular Biology in Type 2 Diabetes Subjects
The main objective is to demonstrate the effects of early dopaminergic activation on the autonomic nervous system in subjects with newly diagnosed vs. established type 2 diabetes.
- Trial name
- NCT02682901
- Testing
- Cycloset
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Eastern Virginia Medical School
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 1356 (Linagliptin) Versus Placebo in Type 2 Diabetic Patients With Insufficient Glycemic Control
To investigate efficacy, safety and tolerability of BI 1356 versus placebo
- Trial name
- NCT00621140
- Testing
- linagliptin
- Where
- 69 sites in Croatia, India and 9 more
- Volunteers
- 503 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone
The purpose of this clinical research study is to learn whether Saxagliptin added to Metformin therapy is more effective than Metformin alone as a treatment for type 2 diabetic subjects who are not sufficiently controlled with…
- Trial name
- NCT00121667
- Testing
- Saxagliptin + Metformin, Pioglitazone
- Where
- 152 sites in United States, Argentina and 7 more
- Volunteers
- 1,462 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Exeantide in Type 2 Diabetes on Insulin
Exenatide has been shown to result in better glycemic control in type II diabetes patients. Obesity and diabetes are states of increased inflammation; exenatide is expected to lead to decreased inflammation by virtue of better…
- Trial name
- NCT01154933
- Testing
- exenatide 5 mcg, exenatide 10 mcg
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University at Buffalo
Diabetes, Diabetes Mellitus, Type 2
Efficacy and Safety of Basal-bolus Therapy, Comparing Stepwise Addition of Insulin Aspart Versus Complete Basal-bolus Regimen
This trial is conducted in Europe, and North and South America. The aim of this clinical trial is to investigate if the two treatments are equally effective.
- Trial name
- Full STEP™ (NCT01165684)
- Testing
- insulin aspart, insulin detemir
- Where
- 67 sites in United States, Argentina and 5 more
- Volunteers
- 401 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus
Study Evaluating Safety, Tolerability, And Action Of OAP-189 In Subjects With Type 2 Diabetes On Metformin
This is a study to evaluate the safety, tolerability, and activity of OAP-189 in subjects with type 2 diabetes who are taking metformin for their diabetes.
- Trial name
- 3283K1-1008-US (NCT00970593)
- Testing
- OAP-189
- Where
- 2 sites in United States
- Volunteers
- 92 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2
A Study of PF-05175157 in Healthy Volunteers and Type 2 Diabetic Patients
The primary purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of PF-05175157 in healthy volunteers and patients with type 2 diabetes mellitus.
- Trial name
- NCT01396161
- Where
- 3 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Pfizer
Type 2 Diabetes Mellitus
Insulin Glargine Versus Twice-Daily NPH
To compare the efficacy and safety of once-nightly insulin glargine versus twice-daily NPH insulin in ethnic minority type 2 diabetic patients inadequately treated with once-nightly NPH insulin alone.
- Trial name
- NCT00687453
- Testing
- Insulin glargine at bedtime instead of NPH, NPH twice-daily
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Charles Drew University of Medicine and Science
Type 2 Diabetes Mellitus
Study of the Durability of Glycemic Control With Nateglinide
This multi-center, randomized controlled study aims to evaluate the durability and efficacy of nateglinide therapy for long term glycemic control compared with glimepiride.
- Trial name
- NCT00858013
- Testing
- Nateglinide, Glimepiride
- Where
- 7 sites in South Korea
- Volunteers
- 88 people
- Sponsor
- Ajou University School of Medicine
Acute Coronary Syndrome
Evaluation of Cardiovascular Outcomes in Patients With Type 2 Diabetes After Acute Coronary Syndrome During Treatment With AVE0010 (Lixisenatide)
Primary Objective: To demonstrate that lixisenatide can reduce cardiovascular (CV) morbidity and mortality (composite endpoint of CV death, non-fatal myocardial infarction (MI), non-fatal stroke, hospitalization for unstable…
- Trial name
- ELIXA (NCT01147250)
- Testing
- Lixisenatide (AVE0010)
- Where
- 829 sites in United States, Argentina and 47 more
- Volunteers
- 6,068 people
- Sponsor
- Sanofi